Subscribe

Planet 13 Holdings Inc. (PLNH)

USD0.13 0.00 (-0.57%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address 2548 West Desert Inn Road 89109
Las Vegas, NV, US
CEO Robert Allen Groesbeck
Website planet13holdings.com
IPO 2018-07-12
CIK 1813452 ISIN US72707C1080

Explore sections of this company profile

Also trades on Canadian Securities Exchange · PLTH.CN (CAD) Other OTC · PLNH (USD) Other OTC · PLNHF (USD)
Description

Planet 13 Holdings Inc., headquartered in Las Vegas, Nevada, operates as an integrated cannabis enterprise primarily within the Nevada market in the United States. The company manages the entire lifecycle of cannabis products, from cultivation and manufacturing to distribution and sales, catering to both medicinal and recreational consumers. Beyond its core cannabis operations, which include licensed dispensaries, Planet 13 diversifies its business. It also runs a non-cannabis retail store, an event space, and a suite of hospitality ventures: the Trece Eatery + Spirits, a coffee shop, and a pizzeria. Furthermore, Planet 13 offers various client services such as consultation, educational programs, and convenience solutions. The company develops and owns a wide array of cannabis products, encompassing chocolates, gummies, sparkling beverages, vapes, concentrates, and flowers, sold under proprietary brand names like TRENDI, Leaf & Vine, Dreamland, HaHa, and Medizin.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.13 0.00 (-0.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
559.4K
Beta
1.72
Float Shares
227.71M
Free Float %
69.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.52% -0.71% -9.09% -16.67% -18.18% -30.35% -48.15% -78.26% -97.65% -78.46% -78.46%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.13
Ratings Trend (MoM) 67% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 2 0
Hold 0 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-2.47
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -11.2% Q1'26: -24.8% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -25.0% Q1'26: -217.5% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -28.7% Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -29.0% Q1'26: +0.0% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -29.9% Q1'26: +0.0% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +11.4% Q1'26: +0.8% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -2.96× Q1'26: -2.38× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.71) × ERP
WACC = 46% × Ke + 54% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.13
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
3 EPS Ana. 		Dec 2027
3 Rev. Ana.
3 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
2 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
21.17M
est: 20.20M (+4.8%)
63.60M
est: 66.78M (-4.8%)
70.49M
est: 74.36M (-5.2%)
119.49M
est: 117.65M (+1.6%)
104.57M
est: 102.44M (+2.1%)
98.51M
est: 103.52M (-4.8%)
116.41M
est: 116.52M (-0.1%)
103.38M
est: 102.61M (+0.7%)
92.69M
90.11M – 94.47M
-9.7% YoY
99.39M
94.80M – 103.18M
+7.2% YoY
102.34M
98.52M – 105.31M
+3.0% YoY
110.98M
106.84M – 114.20M
+8.4% YoY
114.01M
109.76M – 117.33M
+2.7% YoY
EBITDA
-7.20M
est: -1.36M (-429.2%)
3.51M
est: -4.50M (+178.0%)
3.86M
est: -5.01M (+176.9%)
-3.68M
est: -7.93M (+53.5%)
-14.68M
est: -6.90M (-112.6%)
-4.11M
est: -6.98M (+41.1%)
185.8K
est: -9.06M (+102.1%)
-18.36M
est: -7.98M (-130.1%)
-7.21M
-7.35M – -7.01M
+9.7% YoY
-7.73M
-8.02M – -7.37M
-7.2% YoY
-7.96M
-8.19M – -7.66M
-3.0% YoY
-8.63M
-8.88M – -8.31M
-8.4% YoY
-8.87M
-9.12M – -8.54M
-2.7% YoY
EBIT
-8.19M
est: -3.30M (-148.6%)
538.6K
est: -10.90M (+104.9%)
-1.41M
est: -12.13M (+88.3%)
-7.76M
est: -19.20M (+59.6%)
-25.26M
est: -16.71M (-51.2%)
-16.25M
est: -16.89M (+3.8%)
-12.58M
est: -21.09M (+40.3%)
-29.96M
est: -18.58M (-61.3%)
-16.78M
-17.10M – -16.31M
+9.7% YoY
-17.99M
-18.68M – -17.16M
-7.2% YoY
-18.53M
-19.06M – -17.84M
-3.0% YoY
-20.09M
-20.67M – -19.34M
-8.4% YoY
-20.64M
-21.24M – -19.87M
-2.7% YoY
Net Income
-10.72M
est: -8.59M (-24.8%)
-12.30M
est: -4.49M (-173.8%)
-25.01M
est: -7.42M (-237.0%)
-22.27M
est: -15.56M (-43.1%)
-59.55M
est: -17.21M (-246.0%)
-73.61M
est: -66.85M (-10.1%)
-47.80M
est: -34.72M (-37.7%)
-65.04M
est: -69.09M (+5.9%)
-9.80M
-16.33M – -6.53M
+85.8% YoY
-4.36M
-4.37M – -4.35M
+55.5% YoY
-3.29M
-3.41M – -3.13M
+24.6% YoY
-3.29M
-3.41M – -3.13M
+0.0% YoY
-3.29M
-3.41M – -3.13M
+0.0% YoY
SGA
13.12M
est: 10.09M (+30.0%)
32.15M
est: 33.36M (-3.6%)
34.57M
est: 37.15M (-6.9%)
64.55M
est: 58.78M (+9.8%)
51.52M
est: 51.18M (+0.7%)
47.53M
est: 51.72M (-8.1%)
57.29M
est: 59.65M (-4.0%)
57.08M
est: 52.53M (+8.7%)
47.45M
46.13M – 48.36M
-9.7% YoY
50.88M
48.53M – 52.82M
+7.2% YoY
52.39M
50.44M – 53.91M
+3.0% YoY
56.81M
54.70M – 58.47M
+8.4% YoY
58.37M
56.19M – 60.06M
+2.7% YoY
EPS
-0.11
est: -0.03 (-274.1%)
-0.09
est: -0.02 (-485.1%)
-0.16
est: -0.03 (-530.0%)
-0.12
est: -0.05 (-125.3%)
-0.26
est: -0.06 (-341.4%)
-0.33
est: -0.23 (-44.2%)
-0.16
est: -0.11 (-49.9%)
-0.20
est: -0.21 (+5.8%)
-0.03
-0.05 – -0.02
+85.8% YoY
-0.01
-0.01 – -0.01
+55.5% YoY
-0.01
-0.01 – -0.01
+24.6% YoY
-0.01
-0.01 – -0.01
+0.0% YoY
-0.01
-0.01 – -0.01
+0.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-11 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-08 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-07 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-06 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-05 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-04 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-01 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-29 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-28 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-27 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-24 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-23 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-30.23M
OE per share TTM
-0.09
Owner's Yield
-66.29%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
75.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
4
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 1 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 AdvisorShares Pure US Cannabis ETF MSOS 0.19% 1.74M 0.81%

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.40
Bearish
Ratio by volume
3.00
Bullish
Buys
2
Sells
5
Shares acquired
1.61M
Shares disposed
95.0K
Cash buys
—
Cash sales
5.00
Net activity
+1,518,994
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-05-16 McLean Stephen Officer — — Restricted Stock Unit 450,847 0.00 — 0 D ↗
2026-04-30 Wren Chris Officer S-Sale D Common Stock 30,000 0.15 4.6K 5,017,784 D ↗
2026-04-20 Wren Chris Officer S-Sale D Common Stock 30,000 0.15 4.5K 5,047,784 D ↗
2026-04-17 Wren Chris Officer S-Sale D Common Stock 2,500 0.15 383.50 5,107,784 D ↗
2026-04-16 Wren Chris Officer A-Award A Common Stock 791,997 0.00 — 5,080,284 D ↗
2026-03-06 Wren Chris Officer S-Sale D Common Stock 30,000 0.16 4.9K 4,288,287 D ↗
2026-02-20 Wren Chris Officer S-Sale D Common Stock 30,000 0.17 5.1K 4,318,287 D ↗
2026-01-30 Wren Chris Officer S-Sale D Common Stock 25,000 0.17 4.4K 3,848,287 D ↗
2026-01-23 Wren Chris Officer S-Sale D Common Stock 30,000 0.19 5.6K 3,873,287 D ↗
2026-01-16 Wren Chris Officer S-Sale D Common Stock 30,000 0.18 5.5K 3,903,287 D ↗
2026-01-08 Wren Chris Officer A-Award A Common Stock 500,000 0.00 — 4,348,287 D ↗
2026-01-07 Wren Chris Officer S-Sale D Common Stock 30,000 0.20 6.1K 3,933,287 D ↗
2026-01-02 Wren Chris Officer A-Award A Restricted Stock Unit 1,500,000 0.00 — 3,117,797 D ↗
2026-01-02 Scheffler Larry Director / Officer / 10% Owner A-Award A Restricted Stock Unit 1,500,000 0.00 — 3,449,153 D ↗
2026-01-02 Oganyan Tatev Officer A-Award A Restricted Stock Unit 1,000,000 0.00 — 1,058,000 D ↗
2026-01-02 McLean Stephen Officer A-Award A Restricted Stock Unit 1,000,000 0.00 — 1,450,847 D ↗
2026-01-02 Groesbeck Robert Director / Officer / 10% Owner A-Award A Restricted Stock Unit 1,500,000 0.00 — 3,449,153 D ↗
2025-12-24 Wren Chris Officer S-Sale D Common Stock 30,000 0.23 6.8K 3,993,287 D ↗
2025-12-19 Scheffler Larry Director / Officer / 10% Owner J-Other A Common Stock 720,517 0.23 165.7K 1,283,017 I ↗
2025-12-19 Groesbeck Robert Director / Officer / 10% Owner J-Other D Common Stock 720,517 0.23 165.7K 28,692,659 I ↗
2025-12-15 Wren Chris Officer S-Sale D Common Stock 100,000 0.21 21.2K 4,023,287 D ↗
2025-12-12 Wren Chris Officer S-Sale D Common Stock 100,000 0.18 18.2K 4,123,287 D ↗
2025-12-12 Groesbeck Robert Director / Officer / 10% Owner S-Sale D Common Stock 1,000,000 0.21 208.0K 29,413,176 I ↗
2025-12-11 Wren Chris Officer S-Sale D Common Stock 100,000 0.17 16.8K 4,223,287 D ↗
2025-12-09 Wren Chris Officer S-Sale D Common Stock 37,800 0.18 6.7K 4,323,287 D ↗
2025-12-08 Wren Chris Officer S-Sale D Common Stock 37,324 0.18 6.8K 4,361,087 D ↗
2025-12-04 Wren Chris Officer S-Sale D Common Stock 100,000 0.19 18.6K 4,398,411 D ↗
2025-12-03 Wren Chris Officer S-Sale D Common 100,000 0.19 19.0K 4,498,411 D ↗
2025-12-02 Wren Chris Officer S-Sale D Common 55,500 0.18 10.2K 4,598,411 D ↗
2025-11-25 Wren Chris Officer S-Sale D Common Stock 61,600 0.19 11.8K 4,653,911 D ↗
2025-11-24 Wren Chris Officer S-Sale D Common Stock 38,900 0.19 7.3K 4,476,611 D ↗
2025-11-21 Wren Chris Officer S-Sale D Common Stock 100,000 0.17 17.0K 4,515,511 D ↗
2025-11-20 Wren Chris Officer S-Sale D Common Stock 100,000 0.18 17.5K 4,615,511 D ↗
2025-11-19 Wren Chris Officer S-Sale D Common Stock 100,000 0.16 15.8K 4,715,511 D ↗
2025-11-12 Wren Chris Officer S-Sale D Common Stock 30,000 0.19 5.7K 4,815,511 D ↗
2025-11-04 Wren Chris Officer S-Sale D Common Stock 27,550 0.19 5.4K 4,845,511 D ↗
2025-11-03 Wren Chris Officer S-Sale D Common Stock 2,450 0.20 490.00 4,873,061 D ↗
2025-10-31 Wren Chris Officer S-Sale D Common Stock 30,000 0.20 6.1K 4,875,511 D ↗
2025-10-22 Wren Chris Officer S-Sale D Common Stock 2,200 0.22 484.00 4,903,311 D ↗
2025-10-20 Wren Chris Officer S-Sale D Common Stock 27,800 0.22 6.1K 4,905,511 D ↗
2025-10-09 Wren Chris Officer S-Sale D Common Stock 30,000 0.24 7.3K 4,933,311 D ↗
2025-10-09 Loop David W Director W-Will A Common Stock 805,643 0.00 — 805,643 I ↗
2025-09-29 Wren Chris Officer S-Sale D Common Stock 30,000 0.24 7.2K 4,963,311 D ↗
2025-09-26 Wren Chris Officer S-Sale D Common Stock 30,000 0.21 6.3K 4,993,311 D ↗
2025-09-12 Wren Chris Officer S-Sale D Common Stock 48,600 0.25 12.2K 5,023,311 D ↗
2025-09-11 Wren Chris Officer S-Sale D Common Stock 23,840 0.26 6.2K 5,048,071 D ↗
2025-09-09 Wren Chris Officer S-Sale D Common Stock 42,918 0.28 11.9K 5,071,911 D ↗
2025-09-02 Groesbeck Robert Director / Officer / 10% Owner S-Sale D Common Stock 73,000 0.28 20.2K 5,529,294 I ↗
2025-08-29 Groesbeck Robert Director / Officer / 10% Owner S-Sale D Common Stock 245,000 0.29 71.6K 5,602,294 I ↗
2025-08-28 Groesbeck Robert Director / Officer / 10% Owner S-Sale D Common Stock 370,000 0.30 109.5K 5,847,294 I ↗
2025-08-27 Wren Chris Officer S-Sale D Common Stock 100,000 0.28 28.1K 5,114,829 D ↗
2025-08-27 Groesbeck Robert Director / Officer / 10% Owner S-Sale D Common Stock 108,000 0.28 30.4K 6,217,294 I ↗
2025-08-26 Groesbeck Robert Director / Officer / 10% Owner S-Sale D Common Stock 310,000 0.29 89.2K 6,325,294 I ↗
2025-08-25 Wren Chris Officer S-Sale D Common Stock 100,000 0.29 28.7K 5,214,829 D ↗
2025-08-25 Groesbeck Robert Director / Officer / 10% Owner S-Sale D Common Stock 327,000 0.29 93.6K 6,635,294 I ↗
2025-08-22 Groesbeck Robert Director / Officer / 10% Owner S-Sale D Common Stock 302,000 0.29 86.6K 6,962,294 I ↗
2025-08-21 Wren Chris Officer S-Sale D Common Stock 100,000 0.28 28.3K 5,214,829 D ↗
2025-08-21 Groesbeck Robert Director / Officer / 10% Owner S-Sale D Common Stock 339,000 0.28 94.6K 7,264,294 I ↗
2025-08-19 Wren Chris Officer S-Sale D Common Stock 46,000 0.32 14.9K 5,314,829 D ↗
2025-08-18 Wren Chris Officer S-Sale D Common Stock 100,000 0.31 30.8K 5,360,829 D ↗
2025-08-15 Wren Chris Officer S-Sale D Common Stock 127,000 0.30 38.5K 5,460,829 D ↗
2025-08-14 Fraser Lee Officer S-Sale D Common Stock 100,000 0.29 28.9K 1,852 D ↗
2025-04-02 Wren Chris Officer A-Award A Restricted Stock Unit 1,617,797 0.00 — 1,617,797 D ↗
2025-04-02 Scheffler Larry Director / Officer / 10% Owner A-Award A Restricted Stock Unit 1,949,153 0.00 — 1,949,153 D ↗
2025-04-02 Oganyan Tatev Officer A-Award A Restricted Stock Unit 338,983 0.00 — 638,983 D ↗
2025-04-02 Martin Kevin S Director A-Award A Restricted Stock Unit 338,983 0.00 — 338,983 D ↗
2025-04-02 Loop David W Director / Officer A-Award A Restricted Stock Unit 677,966 0.00 — 677,966 D ↗
2025-04-02 Logan Dennis Officer A-Award A Restricted Stock Unit 991,525 0.00 — 991,525 D ↗
2025-04-02 Groesbeck Robert Director / Officer / 10% Owner A-Award A Restricted Stock Unit 1,949,153 0.00 — 1,949,153 D ↗
2025-04-02 Fraser Lee Officer A-Award A Restricted Stock Unit 1,052,542 0.00 — 1,052,542 D ↗
2025-03-31 O'Neal Adrienne Director A-Award A Restricted Stock Unit 338,983 0.00 — 338,983 D ↗
2024-06-12 Loop David W Director / Officer — I Common Stock 0 0.00 — 12,534,708 — ↗
2024-05-10 Ascik Mark A SR Officer — I Common Stock 0 0.00 — 4,504,683 — ↗
2024-05-10 Ascik Mark A JR Officer — D Common Stock 0 0.00 — 1,501,802 — ↗
2024-03-22 Wren Chris Officer M-Exempt A Common Stock 156,518 0.52 81.2K 461,349 — ↗
2024-03-22 Scheffler Larry Director / Officer / 10% Owner M-Exempt D Restricted Stock Units 281,255 0.52 146.0K 0 — ↗
2024-03-22 Oganyan Tatev Officer A-Award A Restricted Stock Units 300,000 0.00 — 300,000 — ↗
2024-03-22 O'Neal Adrienne Director M-Exempt D Restricted Stock Units 69,494 0.52 36.1K 0 — ↗
2024-03-22 Logan Dennis Officer M-Exempt D Restricted Stock Units 104,345 0.52 54.2K 0 — ↗
2024-03-22 Groesbeck Robert Director / Officer / 10% Owner M-Exempt A Common Stock 281,255 0.52 146.0K 1,239,394 — ↗
2024-03-22 Fraser Lee Director / Officer A-Award A Restricted Stock Units 185,185 0.00 — 0 — ↗
2024-02-07 Oganyan Tatev Officer — — — 0 0.00 — 0 — ↗
2024-02-07 Martin Kevin S Director — — — 0 0.00 — 0 — ↗

Executive team

Top executives
EBIT / Employee
-30.0K
Shares Outstanding
328.17M

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2025 Larry Scheffler Co-Chief Executive Officer 543.3K — — — — 42.0K 585.2K 0.00% ↗
2 2025 Robert Groesbeck Co-Chief Executive Officer 543.3K — — — — 42.0K 585.2K 0.00% ↗
3 2025 Chris Wren Vice President of Operations 411.5K — — — — 33.0K 444.5K 0.00% ↗
4 2025 Tatev Oganyan General Counsel 267.5K — 24.0K — — 33.0K 324.5K 7.40% ↗
5 2025 Steve McLean Interim Chief Financial Officer 204.4K — — — — 26.5K 230.9K 0.00% ↗
6 2024 Robert Groesbeck Co-Chief Executive Officer 500.0K — — — 312.5K 51.2K 863.7K 0.00% ↗
7 2024 Larry Scheffler Co-Chief Executive Officer 500.0K — — — 312.5K 51.2K 863.7K 0.00% ↗
8 2024 Chris Wren Vice President of Operations 415.0K — — — 103.8K 47.1K 565.9K 0.00% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2026-04-29 DEFA14A ↗
2026-04-29 DEF 14A ↗
2025-04-23 DEFA14A ↗
2025-04-23 DEF 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-05 4 ↗
2026-04-30 8-K ↗
2026-04-29 DEFA14A ↗
2026-04-29 DEF 14A ↗
2026-04-29 ARS ↗
2026-04-22 4/A ↗
2026-04-21 4 ↗
2026-03-25 8-K ↗
2026-03-25 10-K ↗
2026-03-10 4 ↗

Executive team

NameTitleCompensationGender
Larry Norman Scheffler Co-Chairman & Co-CEO 585.2K male
Robert Allen Groesbeck Co-Chairman & Co-CEO 585.2K male
Christopher Brian Wren Vice President of Operations 444.5K male
Tatev Oganyan General Counsel & Corporate Secretary 300.5K female
Steve McLean Interim Chief Financial Officer 230.9K male
David Loop Co-President of Florida Operations & Director 100.0K male
Jillian Austin National Head of Marketing Experiences — female
Bryant Ison Vice President of Marketing — male
ESG Rating
B
DRUG MANUFACTURERS - SPECIALTY & GENERIC
Rank: 57 out of 119
2025
E (Environmental)
56.0 / 66.0
Company / Sector avg.
S (Social)
61.7 / 70.0
Company / Sector avg.
G (Governance)
60.5 / 66.6
Company / Sector avg.
ESG Total
59.4 / 67.5
Company / Sector avg.
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic